Oltmans Curtis Gale 4

What Happened
Curtis Gale Oltmans, Chief Legal Officer of Fulcrum Therapeutics (FULC), was granted a derivative award covering 170,000 shares on February 2, 2026. The Form 4 reports the transaction as an award/acquisition (code A) with an amount reported at $0.00 (derivative). This was a grant of equity compensation, not an open-market purchase or sale.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely — within the standard 2 business-day reporting window).
• Security: derivative award covering 170,000 shares; transaction price reported as $0.00 on the Form 4.
• Vesting: per footnote, the option award vests in equal quarterly installments over four years, beginning January 1, 2026, subject to continued service.
• Shares/units owned after transaction: not provided in the summary provided here — see the full Form 4 for post-transaction holdings.
• Filing type/notes: Award (A). No 10b5-1 plan, tax-withholding sale, or immediate sale noted in the provided details.

Context
This was an equity-compensation grant (options/award) rather than a purchase or sale. Such grants typically vest over time and become exercisable only as they vest and/or subject to plan terms, so they do not represent immediate liquidity or open-market buying/selling by the insider. For specifics on exercise price, expiration, or post-transaction ownership, review the complete Form 4 and company equity-plan disclosures.